The influence of finasteride on the development of prostate cancer.
暂无分享,去创建一个
I. Thompson | P. Goodman | C. Tangen | M. Lucia | L. Ford | S. Lippman | C. Coltman | G. Miller | J. J. Crowley | M. Lieber | Connie M Szczepanek | R. Cespedes | A. Ryan | J. Atkins | Susie M. Carlin | I. Thompson
[1] M. Marberger,et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. , 2003, The Journal of urology.
[2] Ricky A. Sharma,et al. Cancer prevention and delay are as important as cure. , 2003, The Lancet. Oncology.
[3] J. Crowley,et al. Biomarker-based methods for determining noncompliance in a prevention trial. , 2002, Controlled clinical trials.
[4] S. Lippman,et al. Cancer prevention science and practice. , 2002, Cancer research.
[5] P. Humphrey,et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.
[6] J. Reichardt,et al. Hormones and prostate cancer: Current perspectives and future directions , 2002, The Prostate.
[7] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.
[8] S. Lippman,et al. Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] R. Prehn. On the prevention and therapy of prostate cancer by androgen administration. , 1999, Cancer research.
[10] Ximing J. Yang,et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? , 1999 .
[11] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[12] J. Hanley,et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.
[13] E. Crawford,et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.
[14] P. Kantoff,et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Soloway,et al. Histopathological effects of androgen deprivation in prostatic cancer. , 1996, Seminars in urologic oncology.
[16] J. Crowley,et al. Design of the Prostate Cancer Prevention Trial (PCPT). , 1995, Controlled clinical trials.
[17] W. Murphy,et al. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone–‐releasing hormone effect). Distinction from poor tumor differentiation , 1994, Cancer.
[18] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[19] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[20] M. Pike,et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males , 1992, The Lancet.
[21] S. Ishikawa,et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.
[22] P. Walsh. Influence of prostate volume in the detection of prostate cancer. , 2003, The Journal of urology.
[23] M. Sporn,et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] Eter,et al. THE EFFECT OF FINASTERIDE ON THE RISK OF ACUTE URINARY RETENTION AND THE NEED FOR SURGICAL TREATMENT AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA , 2000 .
[25] P. Walsh. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. , 1999, The Journal of urology.
[26] D. Bostwick. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. , 1998, Anatomic pathology.
[27] Bostwick Dg. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. , 1998 .
[28] M M Elhilali,et al. Outcome of sextant biopsy according to gland volume. , 1997, Urology.
[29] H A Feldman,et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. , 1994, The Journal of urology.